Immunogenicity and Safety of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India.

Trial Profile

Immunogenicity and Safety of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Dec 2016

At a glance

  • Drugs CYD TDV (Primary)
  • Indications Dengue
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 24 Aug 2016 Last checked against Clinical Trials Registry - India record.
    • 24 Jul 2012 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India.
    • 29 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top